We found that treatment of CLL cells with cortactin-specific siRNA, but not non-specific siRNA, could reduce expression of cortactin and suppress the capacity of Wnt5a to enhance chemokine-directed CLL-cell migration (Fig. 3c, d). The gene discussed is CTTN; the disease is B-cell chronic lymphocytic leukemia.